Vascular calcification biomarkers and peripheral arterial disease

International Angiology

Volumn 35, Issue 5, 2016, Pages 455-456

  Kapetanios, Dimitrios ^a   Karkos, Christos ^a   Giagtzidis, Ioakeim ^a   Papazoglou, Konstantinos ^a   Kiroplastis, Konstantinos ^a   Spyridis, Charalampos ^a  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

Osteoprotegerin Osteopontin; Peripheral arterial disease

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; OSTEOPONTIN; OSTEOPROTEGERIN; SPP1 PROTEIN, HUMAN; TNFRSF11B PROTEIN, HUMAN;

ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CASE CONTROL STUDY; CELLULAR IMMUNITY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; HISTOPATHOLOGY; HUMAN; MEDLINE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROGNOSIS; SYSTEMATIC REVIEW; VASCULAR DISEASE; BLOOD; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; VASCULAR CALCIFICATION;

BIOMARKERS; HUMANS; OSTEOPONTIN; OSTEOPROTEGERIN; PERIPHERAL ARTERIAL DISEASE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; VASCULAR CALCIFICATION; VASCULAR STIFFNESS;

EID: 84982921601     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Bagger YZ, Tanko LB, Alexandersen P, Qin G, Christiansen C; Prospective Epidemiological Risk Factors Study Group. Radiographic measure of aorta calcifi cation is a site-specifi c predictor of bone loss and fracture risk at the hip. J Intern Med 2006;259:598-605.
2. Hak AE, Pols HA, van Hemert AM, Hofman A, Witteman JC. Progression of aortic calcifi cation is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Thromb Vasc Biol 2000;20:1926-31.
3. Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O'Donnell CJ, Wilson PW. Bone loss and the progression of abdominal aortic calcifi cation over a 25 year period: the Framingham Heart Study. Calcif Tissue Int 2001;68:271-6.
4. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V. Aortic calcifi cation and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 2004;89:4246-53.
5. Tanko LB, Bagger YZ, Christiansen C. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int.2003;73:15-20.
6. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lethy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
7. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, et al. Isolation of a novel cytokine from human fi broblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997;234:137-42.
8. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998;95:3597-602.
9. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22:549-53.
10. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lethy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:159-61.
11. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell.1998;93:3597-602.
12. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
13. Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int 2004;74:103-6.
14. Collin-Osdoby P. Regulation of vascular calcifi cation by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004;95:1046-57.
15. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273:14363-7.
16. Gochuico BR, Zhang J, Ma BY, Marshak-Rothstein A, Fine A. et al. TRAIL expression in vascular smooth muscle. Am J Physiol Lung Cell Mol Physiol 2000;278:L1045-50.
17. Sato K, Niessner A, Kopecky SL, Frye RL, Goronzy JJ, Weyand CM. TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J Exp Med 2006;203:239-50.
18. Lai C, Seshadri V, Huang K, Shao JS, Cai J, Vattikuti R, et al. An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells. Circ Res 2006;98:1479-89.
19. Minoretti P, Falcone C, Calcagnino M, Emanuele E, Buzzi MP, Coen E, et al. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 2006;27:802-7.
20. Isoda K, Nishikawa K, Kamezawa Y, Yoshida M, Kusuhara M, Moroi M, et al. Osteopontin plays an important role in the development of medial thickening and neointimal formation. Circ Res 2002;91:77-82.
21. Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S, et al. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 2003;112:1318-31.
22. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001;107:1055-61.
23. Steitz SA, Speer MY, McKee MD, Liaw L, Almeida M, Yang H, et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol 2002;161:2035-46.
24. Ye Z, Ali Z, Klee GG, Mosley TH Jr, Kullo IJ. Kullo Associations of Candidate Biomarkers of Vascular Disease with the Ankle-Brachial Index and Peripheral Arterial Disease. Am J Hypertens 2013;26:495-502.
25. Heymann MF, Herisson F, Davaine JM, Charrier C, Battaglia S, Passuti N, et al. Role of the OPG/RANK/RANKL triad in calcifi cations of the atheromatousplaques: Comparison between carotid and femoral beds. Cytokine 2012;58:300-6.
26. Zagura M, Serg M, Kampus P, Zilmer M, Zilmer K, Eha J, et al. Association of osteoprotegerin with aortic stiffness in patients with symptomatic peripheral artery disease and in healthy subjects. Am J Hypertens 2010;23:586-591.
27. Zagura M, Kals J, Serg M, Kampus P, Zilmer M, Jakobson M, et al. Structural and biochemical characteristics of arterial stiffness in patients with atherosclerosis and in healthy subjects. Hypertens Res 2012;35:1032-7.
28. Singh DK, Winocour P, Summerhayes B, Kaniyur S, Viljoen A, Sivakumar G, et al. Prevalence and progression of peripheral vascular calcifi cation in type 2 diabetes subjects with preserved kidney function. Diab Res Clin Pract 2012;97:158-65.
29. Koshikawa M, Aizawa K, Kasai H, Izawa A, Tomita T, Kumazaki S, et al. Elevated osteopontin levels in patients with peripheral arterial disease. Angiology 2009;60:42-5.
30. Pennisi P, Signorelli SS, Riccobene S, Celotta G, Di Pino L, La Malfa T, et al. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int 2004;15:389-95.
31. Ziegler S, Kudlacek S, Luger A, Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 2005;182:175-80.
32. Gordin D, Soro-Paavonen A, Thomas MC, Harjutsalo V, Saraheimo M, Bjerre M, et al. osteoprotegerin is an independent predictor of vascular events in finnish adults with type 1 diabetes. Diabetes Care 2013;36:1827-33.
33. O'Sullivan EP, Ashley DT, Davenport C, Kelly J, Devlin N, Crowley R, et al. Osteoprotegerin is higher in peripheral arterial disease regardless of glycaemic status. Thrombosis Res 2010;126:423-7.
34. Poulsen MK, Nybo M, Dahl J, Hosbond S, Poulsen TS, Johansen A, et al. Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus. Cardiovasc Diabetol 2011;10:76.
35. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-defi cient mice develop early onset osteoporosis and arterial calcifi cation. Genes Dev 1998;12:1260-8.
36. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcifi cation in older ApoE -/- mice. Arterioscler Thromb Vasc Biol 2006;26:2117-24.
37. Wada T, McKee M, Steitz S, Giachelli C. Calcifi cation of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 1999;84:166-78.